Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?
Could Help Patients Who Lack Own Antibody Response
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.
You may also be interested in...
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
Plus: Humainigen announced data from its still-blinded Phase III trial, while Korea's GeneOne advanced a DNA vaccine candidate.
Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.